Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;107(21):1129-1135.
doi: 10.1024/1661-8157/a003076.

[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma]

[Article in German]
Sigrid Platzer  1 , Thomas Fehr  2 , Tsogyal Latshang  1
Affiliations
Review

[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma]

[Article in German]
Sigrid Platzer et al. Praxis (Bern 1994). 2018.

Abstract
in English, German

CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma Abstract. The challenging therapy of severe uncontrollable bronchial asthma aims primarily at sufficient symptom control and the minimization of the exacerbation rate. If, despite extended drug therapy, symptom control is very difficult to achieve, biologics should preferably be used instead of corticosteroid therapy. The aim of this article is to point out these different asthma therapy pathways and to describe diagnostic criteria as well as practical experiences through application in patients.

Zusammenfassung. Die herausfordernde Therapie eines schweren, unkontrollierbaren Asthma bronchiale hat primär eine ausreichende Symptomkontrolle und die Minimierung der Exazerbationsrate zum Ziel. Ist die Symptomkontrolle trotz ausgebauter medikamentöser Therapie nur sehr schwer zu erreichen, kann anstatt der nebenwirkungsreichen Kortikosteroidtherapie die Indikation für Biologika gestellt werden. Ziel dieses Artikels ist es, diese verschiedenen Asthma-Therapiepfade aufzuzeigen, Diagnosekriterien, aber auch praktische Erfahrungen durch deren Anwendung bei Patienten zu beschreiben.

Keywords: Asthma phenotypes; Asthma-Phänotypen; Asthmakontrolle; Eosinophilie; Interleukin-5-Antikörper; anti-IL5 antibody; eosinophilia; schweres Asthma bronchiale; severe asthma.

PubMed Disclaimer

MeSH terms